Kardigan (KARD) investor relations material

Company overview and business model

• Clinical-stage precision therapeutics company focused on developing medicines targeting the root causes of specific cardiovascular diseases with no approved treatments.

• Pipeline includes three late-stage programs: Danicamtiv (genetic DCM), Ataciguat (moderate CAVS), and Tonlamarsen (post-hospitalization management of ASH).

• Proprietary Prolaio platform integrates real-world patient data and advanced analytics to optimize clinical trial design and execution.

• Business model leverages parallel development of targeted therapies and technology-driven trial acceleration.

Financial performance and metrics

• No revenue generated to date; company remains pre-commercial.

• Net loss of $191.9 million for the year ended December 31, 2025, and $56.1 million for the three months ended March 31, 2026.

• Accumulated deficit of $337.2 million as of March 31, 2026.

• Cash, cash equivalents, and short-term investments totaled $287.1 million as of March 31, 2026.

• Research and development expenses were $153.1 million in 2025, up from $84.3 million in 2024.

• General and administrative expenses were $48.8 million in 2025, up from $12.4 million in 2024.

Use of proceeds and capital allocation

• Net proceeds from the IPO, together with existing cash, will fund clinical development of Danicamtiv, Ataciguat, and Tonlamarsen, as well as other R&D activities.

• Remaining funds allocated to working capital and general corporate purposes; potential for in-licensing or acquisitions.

• Management believes current resources, including IPO proceeds, will fund operations through a specified period, but additional capital will be required for full development and commercialization.